People · Operator
Named in public records as an officer, director or promoter · active 2017–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Urigen Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $7.1M | $6.3M | 2017 |
Carlo Lowell Di Fonzo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carlo Lowell Di Fonzo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| MARK J. ROSENBLUM | 1 | 3 |
| C. Lowell Parsons | 1 | 1 |
| Dan Vickery | 1 | 1 |
| Michael J. Goldberg | 1 | 1 |
| Michael J. Nordlicht | 1 | 1 |
| A. Luc Maasdorp | 1 | 1 |
| Daniel Vickery | 1 | 1 |
| Robert Lowell Evans | 1 | 1 |
| Abe Lowell Hahn | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.